{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:28:19Z","timestamp":1767374899170,"version":"build-2065373602"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":280,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p><jats:bold>Study Objectives.<\/jats:bold> To determine clinical and microbiologic plus clinical success rates in critically ill trauma patients who received treatment for <jats:italic>Stenotrophomonas maltophilia<\/jats:italic> ventilator\u2010associated pneumonia (VAP). Design. Retrospective medical record review.<\/jats:p><jats:p><jats:bold>Setting.<\/jats:bold> Level I trauma intensive care unit of a large academic medical center.<\/jats:p><jats:p><jats:bold>Patients.<\/jats:bold> A total of 101 patients who developed <jats:italic>S. maltophilia<\/jats:italic> VAP between January 1997 and December 2007.<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> Patients' baseline demographic and clinical characteristics, as well as characteristics of their VAP, were documented. The primary study outcome was the rate of clinical success in patients with <jats:italic>S. maltophilia<\/jats:italic> VAP; a secondary outcome was microbiologic plus clinical success rate in these patients. Standard definitions were employed to determine these outcomes related to VAP treatment. The study population had higher injury severity scores and a higher rate of traumatic brain injury than is typically observed in the study's intensive care unit. The median time to diagnosis of <jats:italic>S. maltophilia<\/jats:italic> VAP was 15 days (interquartile range 11\u201324 days). <jats:italic>Stenotrophomonas maltophilia<\/jats:italic> was the sole organism isolated in 34% of patients; the other patients had polymicrobial VAP. Despite inadequate empiric antibiotic therapy being administered to 97% of the patients, the overall clinical success rate was 87%. The microbiologic plus clinical success rate was 82%. The most common treatments for <jats:italic>S. maltophilia<\/jats:italic> VAP were trimethoprim\u2010sulfamethoxazole (77 patients received monotherapy, 9 received combination therapy) and ciprofloxacin (6 patients received monotherapy, 8 received combination therapy); all\u2010cause and VAP\u2010related mortality rates were 13% and 7%, respectively.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Critically ill trauma patients with <jats:italic>S. maltophilia<\/jats:italic> VAP responded well to therapy despite high rates of inadequate empiric antibiotic administration. Trimethoprim\u2010sulfamethoxazole was the most common therapy, but clinical success rates did not differ significantly based on antibiotic selection. This study adds significantly to the available <jats:italic>S. maltophilia<\/jats:italic> VAP outcomes data.<\/jats:p>","DOI":"10.1592\/phco.31.4.338","type":"journal-article","created":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T13:20:02Z","timestamp":1301059202000},"page":"338-345","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical and Microbiologic Outcomes in Trauma Patients Treated for <i>Stenotrophomonas maltophilia<\/i> Ventilator\u2010Associated Pneumonia"],"prefix":"10.1002","volume":"31","author":[{"given":"Quinn A.","family":"Czosnowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Christopher","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis J.","family":"Magnotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin A.","family":"Croce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley A.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy C.","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-006-0243-7"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/320183"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-001-1055-4"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc5063"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.11.014"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.6.1655"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.1.152"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/341022"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2307\/30141224"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TA.0000127769.29009.8C"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2005.6.203"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e31812f6c46"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.9.1054"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e31811ec18e"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2006.021"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/340055"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e31819a06e0"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000297956.27474.9D"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/hl.1999.v28.a96418"},{"issue":"2","key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0163-4453(95)91985-6","article-title":"Xanthomonas maltophilia and Pseudomonas cepacia in lower respiratory tracts of patients in critical care units","volume":"31","author":"Maningo E.","year":"1995","journal-title":"J Infect"},{"issue":"1","key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/jcm.24.1.52-55.1986","article-title":"Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital","volume":"24","author":"Morrison AJ","year":"1986","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/648455"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.2.462"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.1.146"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TA.0000141890.29032.9A"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn301"},{"issue":"4","key":"e_1_2_1_29_2","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV\u2010infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Kaplan JE","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep Recomm Rep"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/599376"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.448"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38028.520995.63"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/430912"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2220"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.168-171.2004"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-3-199602010-00006"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00007"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.31.4.338","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.31.4.338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:03:24Z","timestamp":1761062604000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.31.4.338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1592\/phco.31.4.338"],"URL":"https:\/\/doi.org\/10.1592\/phco.31.4.338","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}